< 1 minute read
May 9, 2023

Roblitinib is an Orally Available Aldehyde Selective for FGFR4

FGF401 (roblitinib)

oral reversible-covalent FGFR4 kinase inhibitor first sel. FGFR4i in clinical studies; for HCC from biochemical HTS and SBDD J. Med. Chem., Oct. 1, 2020 Novartis, Basel, CH


Molecules of the Month

MOTY Nominees

Molecule of the Year